SLC39A11 and bladder transitional cell carcinoma: Between 10 and 15% of the patients presenting lung squamous cell carcinoma, bladder urothelial carcinoma, esophageal carcinoma, uterine corpus endometrial and cervical squamous cell and endocervical carcinomas are also among the groups presenting increased expression of ZIP11 (Supplementary Figure S1C).